Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/18/2009

Operating expenses: Cost of sales (excludes amortization) 5,224 11,665 18,359 52,509 Research and development 24,015 25,733 78,600 93,291 Selling, general and administrative 23,891 28,730 77,539 106,566 Amortization of intangible assets 1,093 1,093 4,371 4,371 Total operating expenses 54,223 67,221 178,869 256,737 Income (loss) from operations (9,369) 32,056 (57,288) 39,756 Equity in the income (loss) of BioMarin/Genzyme LLC 9,366 (579) 30,525 (2,270) Interest income 7,383 3,231 25,932 16,388 Interest expense (4,080) (4,096) (14,243) (16,394) Impairment loss on investment -- (4,056) -- (4,056) Income (loss) before income taxes 3,300 26,556 (15,074) 33,424 Income Taxes 729 2,050 729 2,593 Net income (loss) $2,571 $24,506 $(15,803) $30,831 Net income (loss) per share, basic $0.03 $0.25 $(0.16) $0.31 Net income (loss) per share, diluted $0.03 $0.21 $(0.16) $0.29 Weighted average common shares outstanding, basic 96,931 99,777 95,878 98,975 Weighted average common shares outstanding, diluted 101,193 128,296 95,878 103,572

The following is the stock-based compensation expense included in the respective captions of the consolidated statements of operations above:

                                           Three Months
                                              Ended         Twelve Months
                                           December 31,  
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
2. BioMarin to Present at the Piper Jaffray Healthcare Conference
3. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
4. BioMarin to Present at the Credit Suisse Healthcare Conference
5. BioMarin Announces Third Quarter 2008 Financial Results
6. BioMarin Corrects Information Included in Bloomberg Article
7. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Citi Biotech Day
10. BioMarin Announces Roll-Out of National PKU Registry
11. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... & Boston, MA (PRWEB) July 28, 2014 ... agreements with two researchers to further develop potential treatments ... malignant brain tumor, in combination with their patented vaccine ... ITI and Duke University, are based on the work ... Division of Neurosurgery at The Preston Robert Tisch Brain ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... The National Model Aviation Museum, located at ... to announce that it has been granted full civilian ... States Air Force. , The certification is the culmination ... spring with an on-site inspection by Sarah Sessions, Museum ... National Museum of the United States Air Force ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... for Design Excellence and Patient Ease-of-Use, BROOKFIELD, ... ) today won the 2008 Medical Design Excellence ... device. The Genesis DM won in the,rehabilitation and ... remote patient monitoring device is,ideal for both the ...
... April 7, 2008 Replikins Ltd. has found that ... has recently,increased to 7.6 (plus/minus 1.4), its highest level ... A rising Replikin Count of a particular,influenza strain, indicating ... has been followed consistently by an outbreak of the ...
... 7, 2008 A,cross-disciplinary research team at the University ... microscopic drug research platform can,produce the chemical reactions needed ... enzyme on a tiny "biochip" created to mimic,the environment ... normally,would. This means that the researchers can proceed to ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 3U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 4
(Date:7/28/2014)... calls himself the bug hunter, but the target of ... found and identified with special methods and instruments. Benjamin ... Veterinary Diagnostic Laboratory at Kansas State University, recently published ... G, which is an important find in the United ... but didn,t know what it was," Hause said. "We ...
(Date:7/28/2014)... 2014)The Brain & Behavior Research Foundation today announced ... Prizes, recognizing exceptional clinical and basic research by ... Young Investigator Grants. The grants enable early career ... psychosocial research for the prevention, early detection, treatment, ... in four people. , Six young scientistswinners of ...
(Date:7/28/2014)... to prevent and treat HIV infection has been problematic ... molecules can arouse as they get rid of the ... Weizmann Institute and the National Institutes of Health (NIH) ... interferons around the time of infection could ... Their research appeared in Nature . , ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2
... working on the fundamental biological processes of plants could ... many parts of the world. Using model plant species, ... uncovered one of the processes used by the plants ... discoveries are now being applied to improve the productivity ...
... geochemists from the University of Southern California and Rice ... that could power spy drones that fit in the ... long been interested in micro-scale air vehicles ?some as ... the lack of a suitable, compact power source. With ...
... at the Max Planck Institute of Biochemistry in Martinsried, ... that blocking blood vessel development in a tumour slows ... principle led to the development of SUTENT®, whose active ... use in the United States, and it is expected ...
Cached Biology News:Sun protection for plants 2USC, Rice to develop bacteria-powered fuel cells 2Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: